2025年12月10日，港股市场上演"惊魂逆转"行情，早盘受外围流动性担忧拖累大幅下探，午后在南向资 金抄底与政策预期升温推动下快速反弹，主要指数全线翻红。截至发稿时间，恒生指数报25466.57点， 较前一交易日上涨32.34点，涨幅0.127%，早盘曾最低跌至25257.61点，单日振幅超400点；恒生科技指 数上涨21.83点，涨幅0.393%，早盘最大跌幅一度达2.1%；恒生中国企业指数同步反弹，报8939.42点。 反映资金午后入场积极性显著提升。 板块与个股层面，早盘领跌的科技、消费股午后集体回血。科技股中，阿里巴巴（09988.HK）早盘跌 3.8%，收盘转涨1.2%，报79.5港元，单日振幅超5%；美团-W（03690.HK）从跌2.5%反弹至涨2.1%，快 手-W（01024.HK）、百度集团-SW（09888.HK）均实现"由跌转涨"，涨幅分别达1.8%、1.5%。消费股 方面，泡泡玛特（09992.HK）午后跌幅收窄至1.3%，较早盘4.2%的跌幅显著修复；周大福 （01929.HK）、呷哺呷哺（00520.HK）午后翻红，分别涨0.8%、0.5%。此前暴跌的个股也出现反弹， 中国中冶（ ...

12月10日早盘，港股市场几乎平开，截至发稿，恒生指数报25435.49点，涨幅约0.00%，恒生科技指数 报5552.35点，跌幅0.04%。新股宝济药业-B高开超129%，复星医药早盘涨超4%，其控股子公司就相关 产品授予辉瑞全球独家许可，将获1.5亿美元首付款及最高19.35亿美元里程碑付款。科网、航空、黄 金、内房股表现不一。摩根大通预计到2026年底，MSCI中国指数涨约18%，沪深300指数涨约12%， MSCI香港指数涨幅可达18%，明年三大指数盈利增长率在9%至15%。汇丰私人银行将恒生指数2026年 底目标设为31000点。中信证券认为2026年港股将开启第二轮估值修复。(AI生成) 来源：视频滚动新闻 ...

Group 1 - The Hang Seng Index opened flat, while the Hang Seng Tech Index fell by 0.04%. Notably, tech stocks were active with Meituan rising by 1.08% and Baidu Group increasing by 0.91%. In the pharmaceutical sector, Fosun Pharma surged by 4.19% [1] - Haitong International believes that after market consolidation, a rebound is expected to continue, with room for tech recovery. The firm suggests that the rebound's strength will depend on policy implementation and potential interest rate cuts by the Federal Reserve. There is a caution regarding the risk of profit-taking if the market anticipates good news too early [1] - Everbright Securities indicates that after a rebound in 2025, the current valuation of the Hang Seng Index is above its 5-year average, reflecting a reasonable valuation range. The tech index has just returned to its 5-year average, suggesting there is still room for valuation catch-up. The firm predicts that the Hang Seng Index could exceed 30,000 points next year [1] Group 2 - Guotai Junan Securities states that the short-term adjustment in the Hong Kong stock market opens up space for a market rise in 2026. In terms of capital flow, over 110 billion RMB of southbound funds have net flowed into the Hong Kong stock market in November. This indicates strong liquidity and a strong willingness from mainland investors to position themselves in the Hong Kong market at lower levels [2] - The firm forecasts that the Hong Kong stock market could operate between 30,000 and 32,000 points in 2026 [2]

● 本报记者 谭丁豪 2025年港股步入估值修复与结构重塑并行阶段，估值低估、资金错位与业绩分化成为核心特征。历经此 前三年调整，恒生指数形成显著的估值洼地，南向资金创纪录净流入与外资转向共同重塑资金格局。 日前，中信证券海外策略首席分析师徐广鸿在接受中国证券报记者专访时表示，2026年港股将在政策红 利与外部风险博弈中开启第二轮估值修复，内外因素共振有望进一步打开上行空间。在此背景下，投资 需紧扣"业绩确定性+估值弹性"主线，科技、医药、资源品与必选消费四大赛道，凭借政策支撑、产业 景气或供需优势，成为把握港股修复行情的核心方向。 估值洼地凸显 今年以来，港股三大指数震荡上行。Wind数据显示，截至12月9日，恒生指数、恒生中国企业指数、恒 生科技指数分别累计涨幅为49.20%、22.59%、24.32%。 "今年港股市场整体呈现估值修复的态势，有业绩支撑的行业估值扩张更为显著，例如原材料板块。在 此背景下，具有进一步基本面支撑的行业有望获得更大的估值上行空间。"徐广鸿说。 "当前港股正处于估值修复与结构重塑的关键阶段，估值低估、资金错位与业绩分化构成市场核心特 征。"徐广鸿表示，从估值维度看，2021年春 ...

12月5日，港股股指低开探底后震荡回升，截止午盘，恒生指数跌0.25%报25872.09点，恒生科技指数跌 0.2%报5604.24点，国企指数跌0.14%报9093.93点，红筹指数跌0.43%报4231.87点。 信利国际(00732.HK)：前11个月累计综合营业净额约为152.59亿港元，同比减少约6.2%。 盘面上，大型科技股走势分化，阿里巴巴跌0.32%，腾讯控股跌0.82%，京东集团涨0.17%，小米集团涨 1.48%，网易跌1.01%，美团跌0.92%，快手涨0.22%，哔哩哔哩跌0.79%。电力设备股涨幅居前，金风科 技涨超6%；有色金属板块普涨，江西铜业涨超5%；航空股走弱，南方航空跌超2%；今日两只新股上 市，遇见小面跌超27%，天域半导体跌超24%。 企业新闻 碧桂园(02007.HK)境内外债务重组基本落地，降债超900亿元。 遇见小面(02408.HK)每股发售价7.04港元，香港公开发售获425.97倍认购。 龙光集团(03380.HK)：累计已有债券面值136.6亿元得到债务重组要约获配。 绿城中国(03900.HK)：前11个月总合同销售金额约2235亿元，同比减少9.44% ...

Group 1 - The Hong Kong stock market has shown strong performance, with a significant rebound expected in 2025, primarily driven by southbound capital from mainland investors [1] - Southbound capital has reached a record net inflow of 1.38 trillion HKD this year, contributing to a nearly 30% increase in the Hang Seng Index and over 25% in the Hang Seng Tech Index [1] - The popularity of ETFs has surged, with notable inflows into technology and thematic ETFs, reflecting high confidence among mainland investors in the tech sector [1] Group 2 - The convenience of accessing the Hong Kong stock market for mainland investors has been a key factor in the significant growth of ETF investments this year [2] - The deepening of the mutual market access mechanism and the proliferation of financial technology have made it easier for investors to open accounts and trade [2] - The outlook for southbound capital remains positive, particularly in sectors like technology, internet, pharmaceuticals, and high-end manufacturing, as the market continues to recover [2] Group 3 - Baihui Financial Holdings operates Baihui Securities, which is licensed by the Hong Kong Securities and Futures Commission for regulated activities [3] - Baihui Capital holds multiple licenses and has sponsorship qualifications, enhancing its capabilities in the financial market [3]

Core Viewpoint - Recently, Hailan Home officially submitted its listing application to the Hong Kong Stock Exchange, aiming for an "A+H" listing. As of November 24, 2023, 16 companies have achieved "A+H" listings this year, with over 140 A-share companies proposing plans to list in Hong Kong or spin off subsidiaries for a Hong Kong listing. This trend reflects the dual opening of capital markets and the strategic choice for companies to transition from "Chinese brands" to "global brands" [1][2]. Group 1: A-share Companies Listing in Hong Kong - A-share companies, including Hailan Home and Dashang Co., are increasingly announcing plans to list in Hong Kong, with over 140 companies having proposed such plans this year [2]. - The total amount raised through IPOs in Hong Kong has exceeded HKD 200 billion this year, making it the leading global exchange for IPO fundraising [2]. - Leading A-share companies like CATL, Hengrui Medicine, and Haitian Flavoring have joined the "A+H" listing ranks, indicating a strong trend towards internationalization [2]. Group 2: Role of Chinese Securities Firms - Chinese securities firms have captured over 60% of the market share in Hong Kong's IPO underwriting, leveraging their extensive resources and familiarity with regulatory frameworks [3]. - Major Chinese institutions like CICC and CITIC Securities have ranked highly in the Hong Kong IPO underwriting list, reflecting their dominant position in this market [3]. - There is a growing trend of A-share companies seeking consultations from institutions for their Hong Kong listings, indicating a robust pipeline of potential IPOs [3]. Group 3: Impact on the Chinese Securities Industry - The current IPO boom in Hong Kong has significantly impacted the Chinese securities industry, enhancing their ability to meet cross-border financing needs and increasing international competitiveness [4]. - Chinese securities firms are forming a "one-stop overseas service chain" by collaborating with domestic and international legal and auditing resources, providing strong support for mainland companies going international [4]. - The recovery of market sentiment and valuation in the Hong Kong market is attracting more A-share companies to consider listings [4]. Group 4: Future Outlook for Hong Kong Listings - The number of A-share companies listing in Hong Kong is expected to remain high, supported by favorable policies and the strategic positioning of leading enterprises [5]. - Recent measures by the Ministry of Finance and the China Securities Regulatory Commission to expand the list of qualified auditing firms for H-share companies will enhance the quality of auditing services available for companies seeking to list in Hong Kong [5]. - The ongoing trend of "A+H" listings is attributed to a flexible policy environment and the strategic quality improvements of companies, with expectations for Hong Kong to evolve into a platform for the internationalization of Chinese assets [5].

Core Viewpoint - The Hong Kong stock market has been experiencing a correction since the fourth quarter, with significant declines in major indices, yet there is a notable trend of increasing investment from southbound funds, indicating a strong buying interest despite the downturn [1][2][3]. Group 1: Market Performance - As of November 24, the Hang Seng Index has dropped over 4%, while the Hang Seng Technology Index and the Hong Kong Innovative Drug Index have fallen more than 14% and 15% respectively [1][3]. - Southbound funds have shown a consistent net buying trend, with 28 trading days of net purchases and only 4 days of net sales since the beginning of the fourth quarter [2][3]. Group 2: Fund Flows - In the last seven days, southbound funds have accumulated a net purchase of over 60 billion HKD, bringing the total net buying for the year to 1.37 trillion HKD, which is nearly 70% higher than the total net buying of 807.8 billion HKD in the previous year [2][3]. - Cross-border ETFs related to Hong Kong stocks have seen significant inflows, with the top ten ETFs experiencing a combined net purchase of nearly 7 billion HKD in the fourth quarter [1][3]. Group 3: Investment Sentiment - Despite the market correction, there is a strong appetite for quality assets in the Hong Kong market, particularly in sectors aligned with industry trends such as artificial intelligence and innovative pharmaceuticals [4][5]. - Analysts suggest that the current adjustments are viewed as short-term phenomena, influenced by factors such as tightening dollar liquidity and concerns over potential bubbles in the AI sector, rather than fundamental deterioration [5].

Group 1 - The core viewpoint of the articles highlights the strong performance of the Hang Seng Technology ETF (513130) amid fluctuating market conditions, driven by investor interest in Hong Kong tech assets and the resilience of leading tech companies in their Q3 earnings reports [1][2]. - The Hang Seng Technology Index is currently at a historically low valuation, with a PE ratio of 21.57, significantly lower than the Sci-Tech 50 Index and the Nasdaq, indicating a notable valuation advantage [2]. - The Hang Seng Technology ETF has seen substantial inflows, with a net inflow of 171 billion yuan in the first 14 trading days of November, reflecting strong investor sentiment towards the tech sector [1][2]. Group 2 - The Hang Seng Technology ETF (513130) offers multiple advantages, including large scale, good liquidity, and a low management fee of 0.2% per year, making it an important tool for investors looking to gain exposure to core Hong Kong tech assets [3]. - The management company, Huatai-PB Fund, is one of the first ETF managers in China, with extensive experience in managing various successful ETFs, enhancing investor confidence in the product [3].

Core Viewpoint - The report from CITIC Securities indicates that the Hong Kong stock market is expected to experience a second round of valuation recovery and further earnings revival by 2026, driven by a rebound in the fundamental outlook and significant valuation discounts [1] Long-term Investment Directions - Technology sector, including AI-related sub-sectors and consumer electronics [1] - Healthcare sector, particularly biotechnology [1] - Resource products benefiting from rising overseas inflation expectations and de-dollarization, including non-ferrous metals and rare earths [1] - Consumer staples sector, which is relatively stagnant and undervalued, is expected to see valuation recovery [1] - Paper and aviation sectors benefiting from the appreciation of the Renminbi [1]